2. The immune system is strong
Scientists who try to use vaccines often focus on antibodies and their ability to prevent the virus from invading cells. In laboratory tests, they mixed blood from people who had received the virus or a cell vaccine in a bowl to see if antibodies in the blood could “inhibit” the virus. This is easy to do. But antibodies are “the smallest piece of the body’s immune system,” says Jennifer Dowd, an epidemiologist and historian at Oxford University.
T cells also play a key role in preventing infection. These cells do not fight off the virus, but they can locate infected cells and destroy them. This helps to prevent serious infections. And data from people who have been on covid-19 suggest that the T-cell response should provide adequate protection against many strains of SARS-CoV-2.
3. When people are vaccinated against the virus, they are protected against serious side effects
The vaccine is amazing. But “the most important thing is to get people out of the hospital and get out,” Friedrich said. And there is good evidence that current vaccines do the same. In South Africa, one dose of Johnson & Johnson vaccine provided 85% protection against covid-19-related hospitals and deaths. At that time, 95% of cases were filed with type B.1.351. In Israel, where B.1.1.7 has been a major problem, Pfizer Dosage provides 97% protection against covid-19 infections as well as covid-19-linked doses.
4. The same change is still evident
Once the virus enters a cell, it relapses. The more productive the copy, the more likely it is that unreadable errors, or changes, arise. Most of these errors are unnecessary. Few, however, are able to give the virus a leg. For example, the protein mutation known as D614G appears to support the transmission of SARS-CoV-2. Another, E484K, may be able to help the patient not recognize the body’s response. If the viruses that carry these mutations are transmitted from one person to another, they can begin to defeat viruses that do not have them, a process called natural selection. This is how B.1.1.7 type, which is most prevalent, has become a major problem in the US.
In the case of SARS-CoV-2, mutations that make the virus developing in various parts of the world, a phenomenon known as mutant mutations. “We are seeing the same combination change over and over again,” says Vaughn Cooper, a regenerative biologist at the University of Pittsburgh. Just think of the Tetris game, Cooper wrote a recent Scientific American article. “Less infrastructure can be integrated in a variety of ways, combining in a variety of ways, to achieve the same results.”
Cooper and other researchers see this evidence of cognitive evolution as a reliable indicator: the virus could be eliminated with new ways of changing the environment. “It’s really a small balcony right now,” he says. “If we can prevent disease, those cards will still be scarce.”
5. If the effectiveness of the vaccine starts to weaken, we can shoot ourselves.
Finally, current vaccines may not be as effective. “This is to be expected,” Chandran said. But he hopes this will happen gradually: “There will be a vaccination period for the next generation.” Moderna has already begun testing the effectiveness of a propelled rifle aimed at defense against B.1.351 (first known in South Africa). Last week the company produced preliminary results. The current third dose of covid-19 or a supplement of B.1.351 has increased immunity to the first known strains in South Africa and Brazil. But the new booster caused the immune system to be resistant to B.1.351 more than a third of the original shot.
Then relief for a number of reasons. First, it shows that additional components can work. “I think the ability of a RNA-vaccinated vaccine to produce supplements is beneficial to our health,” says Cooper.